Recognition of Streptococcus pneumoniae and muramyl dipeptide by NOD2 results in potent induction of MMP-9, which can be controlled by lipopolysaccharide stimulation

Infection and Immunity

Volumn 82, Issue 12, 2014, Pages 4952-4958

  Vissers, Marloes ^a   Hartman, Yvonne ^a   Groh, Laszlo ^a   de Jong, Dirk J ^a   de Jonge, Marien I ^a   Ferwerda, Gerben ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; GELATINASE B; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MURAMYL DIPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MMP9 PROTEIN, HUMAN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; NOD2 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; MORAXELLA CATARRHALIS; NONHUMAN; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; STREPTOCOCCUS PNEUMONIAE; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL CULTURE; CROHN DISEASE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; CELLS, CULTURED; CROHN DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; NOD2 SIGNALING ADAPTOR PROTEIN; STREPTOCOCCUS PNEUMONIAE;

EID: 84911367768     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02150-14     Document Type: Article

References (39)

1. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. 2001. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 69:851-859.
2. Ram M, Sherer Y, Shoenfeld Y. 2006. Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol. 26:299-307. http://dx.doi.org/10.1007/s10875-006-9022-6.
3. Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, Szegli G. 2003. Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J. Autoimmun. 20:323-331. http://dx.doi.org/10.1016/S0896-8411(03)00037-4.
4. Hong J-S, Greenlee KJ, Pitchumani R, Lee S-H, Song L-Z, Shan M, Chang SH, Park PW, Dong C, Werb Z. 2011. Dual protective mechanisms of matrix metalloproteinases 2 and 9 in immune defense against Streptococcus pneumoniae. J. Immunol. 186:6427-6436. http://dx.doi.org/10.4049/jimmunol.1003449.
5. Böttcher T, Spreer A, Azeh I, Nau R, Gerber J. 2003. Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci. Lett. 338:201-204. http://dx.doi.org/10.1016/S0304-3940(02)01406-4.
6. Rosendahl A, Bergmann S, Hammerschmidt S, Goldmann O, Medina E. 2013. Lung dendritic cells facilitate extrapulmonary bacterial dissemination during pneumococcal pneumonia. Front. Cell. Infect. Microbiol. 3:21. http://dx.doi.org/10.3389/fcimb.2013.00021.
7. Oggioni MR, Memmi G, Maggi T, Chiavolini D, Iannelli F, Pozzi G. 2003. Pneumococcal zinc metalloproteinase ZmpC cleaves human matrix metalloproteinase 9 and is a virulence factor in experimental pneumonia. Mol. Microbiol. 49:795-805. http://dx.doi.org/10.1046/j.1365-2958.2003.03596.x.
8. Vissers M, Habets MN, Ahout IM, Jans J, de Jonge MI, Diavatopoulos DA, Ferwerda G. 2013. An in vitro model to study immune responses of human peripheral blood mononuclear cells to human respiratory syncytial virus infection. J. Vis. Exp. 2013:e50766. http://dx.doi.org/10.3791/50766.
9. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278: 8869-8872. http://dx.doi.org/10.1074/jbc.C200651200.
10. Cockeran R, Mitchell T, Feldman C, Anderson R. 2009. Pneumolysin induces release of matrix metalloproteinase-8 and-9 from human neutrophils. Eur. Respir. J. 34:1167-1170. http://dx.doi.org/10.1183/09031936.00007109.
11. Schaaf B, Liebau C, Kurowski V, Droemann D, Dalhoff K. 2008. Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity.BMC Pulm. Med. 8:12. http://dx.doi.org/10.1186/1471-2466-8-12.
12. Hu J, Van den Steen PE, Dillen C, Opdenakker G. 2005. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol. 70:535-544. http://dx.doi.org/10.1016/j.bcp.2005.04.047.
13. Nabata A, Kuroki M, Ueba H, Hashimoto S, Umemoto T, Wada H, Yasu T, Saito M, Momomura S-I, Kawakami M. 2008. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque. Atherosclerosis 196:129-135. http://dx.doi.org/10.1016/j.atherosclerosis.2007.03.003.
14. Saren P, Welgus HG, Kovanen PT. 1996. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 157:4159-4165.
15. Lappas M. 2013. NOD1 and NOD2 regulate proinflammatory andprolabor mediators in human fetal membranes and myometrium via nuclear factor-kappa B 1. Biol. Reprod. 89:14. http://dx.doi.org/10.1095/biolreprod.113.110056.
16. Lai W-C, Zhou M, Shankavaram U, Peng G, Wahl LM. 2003. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signalregulated kinase 1/2 mitogen-activated protein kinases. J. Immunol. 170: 6244-6249. http://dx.doi.org/10.4049/jimmunol.170.12.6244.
17. Netea MG, Ferwerda G, de Jong DJ, Werts C, Boneca IG, Jéhanno Van Der Meer MJW, Mengin-Lecreulx D, Sansonetti PJ, Philpott DJ. 2005. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2-but also Nod1-activating peptidoglycan agonists. J. Biol. Chem. 280:35859-35867. http://dx.doi.org/10.1074/jbc.M504924200.
18. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. 2006. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J. Leukoc. Biol. 80:267-277. http://dx.doi.org/10.1189/jlb.1105626.
19. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163:1-5.
20. Lee KS, Scanga CA, Bachelder EM, Chen Q, Snapper CM. 2007. TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell. Immunol. 245:103-110. http://dx.doi.org/10.1016/j.cellimm.2007.04.003.
21. Li YY, McTiernan CF, Feldman AM. 2000. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res. 46:214-224. http://dx.doi.org/10.1016/S0008-6363(00)00003-1.
22. Delany AM, Brinckerhoff CE. 1992. Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts. J. Cell. Biochem. 50: 400-410. http://dx.doi.org/10.1002/jcb.240500409.
23. Overall C, Wrana J, Sodek J. 1991. Transcriptional and posttranscriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J. Biol. Chem. 266:14064-14071.
24. Genersch E, Hayess K, Neuenfeld Y, Haller H. 2000. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and-independent pathways. J. Cell Sci. 113:4319-4330.
25. Gordon GM, Ledee DR, Feuer WJ, Fini ME. 2009. Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. J. Cell. Physiol. 221:402-411. http://dx.doi.org/10.1002/jcp.21869.
26. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, Hirtenlehner K, Seifert M, Kubista E. 2002. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res. Treat. 72:69-77. http://dx.doi.org/10.1023/A:1014918512569.
27. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Danø K. 1996. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int. J. Cancer 65:57-62. http://dx.doi.org/10.1002/(SICI)10 97-0215(19960103)65:157::AID-IJC10>3.0.CO;2-F.
28. Yen J-H, Khayrullina T, Ganea D. 2008. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 111:260-270. http://dx.doi.org/10.1182/blood-2007-05-090613.
29. Yan L, Borregaard N, Kjeldsen L, Moses MA. 2001. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL) modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276: 37258-37265. http://dx.doi.org/10.1074/jbc.M106089200.
30. Woolley DE, Roberts DR, Evanson JM. 1976. Small molecular weight β1 serum protein which specifically inhibits human collagenases. Nature 261: 325-327. http://dx.doi.org/10.1038/261325a0.
31. Mtairag EM, Chollet-Martin S, Oudghiri M, Laquay N, Jacob M-P, Michel J-B, Feldman LJ. 2001. Effects of interleukin-10 on monocyte/ endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc. Res. 49:882-890. http://dx.doi.org/10.1016/S0008-6363(00)00287-X.
32. Woessner JF. 1991. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:2145-2154.
33. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. 1994. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 83:799-807.
34. Moestrup SK, Gliemann J, Pallesen G. 1992. Distribution of the α2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 269:375-382. http://dx.doi.org/10.1007/BF00353892.
35. Viallard J, Pellegrin J, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, Ragnaud J, Ling B, Moreau J. 1999. Th1 (IL-2, interferongamma (IFN-)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 115:189-195. http://dx.doi.org/10.1046/j.1365-2249.1999.00766.x.
36. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC. 1997. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J. Immunol. 158:2327-2333.
37. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579-1585. http://dx.doi.org/10.1161/01.CIR.0000058700.41738.12.
38. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L. 2006. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 61:1037-1042. http://dx.doi.org/10.1136/thx.2006.058321.
39. Brand KH, Ahout IM, de Groot R, Warris A, Ferwerda G, Hermans PW. 2012. Use of MMP-8 and MMP-9 to assess disease severity in children with viral lower respiratory tract infections. J. Med. Virol. 84:1471-1480. http://dx.doi.org/10.1002/jmv.23301.